TKT Hopes To "Break Even" In 2006 Following Hunter Syndrome Therapy BLA
The company is "refocusing" on lysosomal storage disease therapies, with a BLA for Hunter syndrome agent I2S expected in 2005, CEO Astrue tells BIO.
The company is "refocusing" on lysosomal storage disease therapies, with a BLA for Hunter syndrome agent I2S expected in 2005, CEO Astrue tells BIO.